A growth-hormone fragment marketed for fat loss. It was developed as an actual obesity drug, the rigorous trials didn't deliver, it's approved nowhere, and it's banned in sport.
AOD-9604 is short for "Anti-Obesity Drug 9604," which tells you exactly what it was built to be. It's a small fragment of human growth hormone, developed by an Australian company (Metabolic Pharmaceuticals, out of Monash University) to isolate the fat-burning part of growth hormone without the growth and blood-sugar effects of the full hormone. That's a genuinely clever idea. The problem is what happened when it was tested. An early human trial showed a modest weight-loss signal, but the later, larger, more rigorous trial didn't reproduce it, and development for obesity was discontinued around 2007. Today it's sold online as a "research compound" for the exact fat-loss use it was designed for and failed to prove. Two things you should know up front: it isn't approved as a drug anywhere, and it's on the World Anti-Doping Agency's banned list, detectable in urine testing. This page walks through what's real and what isn't.
A 16-amino-acid peptide taken from the tail end (the C-terminus) of human growth hormone, residues 176 to 191, with a tyrosine added to one end for stability. Because of that addition it's sometimes written as Tyr-hGH 177-191. It was discovered by Professor Frank Ng and colleagues and pushed through formal drug development by Metabolic Pharmaceuticals. It's closely related to another compound sold as "HGH Fragment 176-191," which lacks that stabilizing tyrosine. They aren't identical, and their study data aren't interchangeable. Whatever is sold online under the name AOD-9604 is not an approved product and wasn't made under pharmaceutical quality controls.
The biological context for AOD-9604 centers on adipose tissue and fat metabolism, and on body composition more broadly. The interest is in a fragment of growth hormone that might influence how the body stores and releases fat without the wider hormonal effects of the full molecule. Read this as a systems-level orientation, not as evidence that the compound reliably changes body composition in people. Mechanism, animal data, and human trial results belong in separate lanes, and this page keeps them apart.
The idea is that AOD-9604 stimulates the breakdown of stored fat (lipolysis) and discourages new fat storage, while leaving the growth-hormone receptor alone, so it doesn't raise IGF-1 or disturb blood sugar the way full growth hormone can. That selectivity is the appealing part. But here's the honest catch: the mechanism is not well understood. The foundational animal study often cited as proof actually found the fat-burning effect was not a direct action on the beta-3 adrenergic receptor, even though the compound raised that receptor's expression. The manufacturer's own later review stated plainly that the mechanism of action isn't understood. So the tidy "it activates beta-3 receptors to burn fat" story you'll read on sales pages oversimplifies the very research it leans on.
Human data. This is the part the marketing skips. Across roughly six human trials involving around 900 people, AOD-9604's safety record was clean and it did not raise IGF-1, which was the whole design goal. On weight loss, an early 12-week trial found a modest effect at a low dose, on the order of a couple of kilograms more than placebo. But the later, larger study that combined the compound with a real diet-and-exercise program did not show that weight-loss effect, and the company discontinued obesity development. For comparison, the modern approved weight-loss drugs (the GLP-1 medications) produce far larger, well-replicated results. After the obesity program ended, the compound was explored for a completely different use, injection into arthritic joints, which is a detail most fat-loss sales pages leave out. The honest summary: interesting idea, solid safety, and efficacy that didn't hold up under rigorous testing.
Preclinical data. The main animal evidence is the foundational mouse work in obese and beta-3-receptor-knockout models. It is often cited as showing a fat-burning mechanism, but it actually found the lipolytic effect was not a direct action on the beta-3 receptor, even as the compound raised that receptor's expression. Preclinical findings like these can motivate human testing, but they do not establish a human outcome, and here the human trials are what ultimately settled the question.
Anecdotal discussion. Online, AOD-9604 is marketed for the exact fat-loss use its own rigorous trial failed to support, and sales pages often lean on a tidy beta-3-receptor story and an "FDA GRAS" label that mean less than they imply. Anecdote and marketing can explain why the compound is visible, but they cannot establish efficacy, product quality, or safety. What is sold online is not the trial compound and was not made under the same controls.
If you compete in any sport governed by anti-doping rules, this matters directly. AOD-9604 is named explicitly on the World Anti-Doping Agency Prohibited List, it's banned at all times both in and out of competition, and laboratories have a validated urine test for it and one of its metabolites. It was at the center of a major Australian sports doping scandal. Using it is an anti-doping rule violation, full stop.
Beyond the anti-doping ban, the biggest limitation is efficacy. The early weight-loss signal did not hold up in the larger, more rigorous trial, obesity development was discontinued, and the mechanism remains poorly understood. The clean safety record and the conditional food-ingredient "GRAS" status are sometimes presented as if they were proof of benefit; they are not. None of the fat-loss marketing rests on a human outcome that held up under rigorous testing.
In the trials, AOD-9604 was well tolerated, with a side-effect profile that was hard to distinguish from placebo, no IGF-1 elevation, and no signs of immune reaction. That's a real and somewhat unusual safety picture. The heavy caveat is that this data came from controlled trials using pharmaceutical-grade material. It says nothing about the purity, dose accuracy, or contamination of the unregulated products sold online under the same name. Nothing here is medical advice.
AOD-9604 shows up in body-composition and fat-loss conversations because a growth-hormone fragment that targets fat without the rest of the hormone's effects is an appealing idea. The honest reading is narrower: it was built and tested for exactly that use and did not prove it in the decisive trial. The useful role for this page is orientation, not encouragement, and for anyone in tested sport the anti-doping status below is the part that matters most.
Across the Aeternus library, the practical standard is claim matching. A mechanism belongs in mechanism language, a cell or animal model belongs in preclinical language, and a human trial belongs in population-specific human-evidence language. This keeps the entry useful for readers who want orientation without turning biology into personal direction. The strongest interpretation is usually the narrowest accurate one: name the pathway, name the evidence type, name the limits, and leave space for uncertainty where the sources do not answer the question. That standard also protects the reader from a common mistake in this category: assuming that biological relevance automatically creates a usable strategy. It does not. Evidence becomes useful when the claim, source type, population, endpoint, and safety context all line up.
It isn't an approved medicine. No regulator anywhere has approved AOD-9604 as a drug for any use. You'll see it described as having "FDA GRAS status," and that's technically about a conditional, self-affirmed determination for use as a food or supplement ingredient. That is not a drug approval, and it is absolutely not evidence that the compound works for fat loss. The US FDA declined to allow it for pharmacy compounding, so it can't be legally compounded there. It also isn't the same thing as the trial compound when you buy it from an online vendor. This page doesn't tell you how to obtain or use it, and nothing here is encouragement to do either.
AOD-9604 is one of the clearest teaching cases in this whole library, which is why we think it's worth reading about even though the bottom line is skeptical. It's a real drug that was developed for exactly what people now buy it for, tested honestly in humans, and quietly shelved when the rigorous trial didn't deliver. The mechanism everyone cites is shakier than it sounds, the "FDA GRAS" talking point means far less than it implies, and it carries a concrete anti-doping risk for anyone who competes. Good safety data is not the same as proven benefit. AOD-9604 has the former and, for fat loss, not the latter.
